FDA Panel Approves Needle-Free Epinephrine Nasal Spray for Anaphylaxis
An FDA advisory panel has approved Neffy, an epinephrine nasal spray produced by ARS Pharmaceuticals Inc., for treating severe allergic reactions, including anaphylaxis, as an alternative to an injection with a needle. The spray is recommended for adults and minors weighing at least 30 kilograms. The company's application now goes to the FDA for approval, with action expected in mid-2023. The spray can treat allergic reactions resulting from food, insect bites or stings, drugs, serum, diagnostic testing substances, and other allergens, as well as idiopathic anaphylaxis and exercise-induced anaphylaxis.